After exciting clinical trial results, Bell Potter has maintained its rating on this exciting ASX healthcare stock.

Detailed price information for Lantheus Holdings (LNTH-Q) from The Globe and Mail including charting and trades.

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

Operator: Thank you for standing by, and welcome to Kyntra Bio, Inc.’s fourth quarter and full year 2025 earnings conference call. At this time, all participants are in a listen-only mode.

In early trade, the ASX 300 stock jumped as much as 17% to $4.26 before pulling back. At the time of writing, the ...

When MRI offered no clear answer in suspected prostate cancer, the use of prostate-specific membrane antigen (PSMA)-PET/CT showed promise for reducing the number of biopsies without compromising the ...

Tagawa, MD, identified 3 primary clinical scenarios where PSMA PET scans have become the established standard for prostate cancer care. The first application is initial s ...

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...

Kyntra Bio(NASDAQ:KYNB) reported that its rebranding, asset sale, and debt payoff have shifted the company’s financial structure and enabled a clinical focus on oncology and rare disease. Management ...

Telix has resubmitted the NDA with the additional data requested by the FDA. The Company believes, based on the Type A meeting and ongoing consultation with the FDA, that the additional data and ...

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation ...